Clinical Trial Update: STOP-HAE: A Phase 3 Study of ADX-324 in HAE [Phase 3]

View source ↗

Summary

A Phase 3 trial (STOP-HAE) evaluating ADX-324 for hereditary angioedema (types I and II) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema
• Hereditary Angioedema Type
• Hereditary Angioedema Type Ii

Drugs mentioned

• ADX-324

Snippet

Sponsor: ADARx Pharmaceuticals, Inc. | Conditions: Hereditary Angioedema, HAE | Phase 3 | Status: RECRUITING